New Glaucoma Drug from Canadian Bio Med Systems and Ocular Therapeutics Pique Interest of Large Pharma Firms
July 9, 2009
Canadian Bio Med Systems Inc. (CBMS). and Ocular Therapeutics announced that Ocular Therapeutics has signed non-disclosure agreements with two unnamed large pharmaceutical firms.
A recent article in “Review of Ophthalmology” supported the development of a new class of glaucoma drugs which is now being tested by CBMS and piqued the interest of these pharmaceutical firms. In this article, David Epstein, MD, Chairman of Ophthalmology at Duke University School of Medicine in Durham North Carolina states that the approach of improving aqueous outflow in the eye is “the most logical approach to treating glaucoma.”
The new compound being developed by CBMS in conjunction with Ocular Therapeutics specifically targets Schlemm’s Canal. This novel approach to treatment may require application of the drug every three months, or less, rather than twice per day. It could revolutionize the treatment for glaucoma.
CBMS is completing the studies required to enter into human clinical trials in both the United States and Canada.
Read the release.
Jump down to form below to submit your own comments